Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen's Elliott Levy On Adaptive Design And Real-World Evidence Strategies

Jun 19 2019

• By Mandy Jackson

Elliott Levy from Amgen — Amgen SVP, Global Development, Elliott Levy • Source: Amgen Inc.

Related Content

FDA Grants Blincyto Accelerated Approval Based On MRD Response Endpoint

Mar 30 2018

A behind-the-scenes look at fastest BLA review in US

May 26 2016

Real-World Evidence At US FDA: Bavencio, Blincyto Approvals Point Way Toward Broader Use

Aug 08 2018

2Q EARNINGS: Amgen cutting up to 2,900 jobs to reinvest in pipeline

Jul 30 2014

Lower-Cost Competitors Hit Amgen's Blockbusters

May 01 2019

Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price

Apr 16 2019

Amgen hits new high on investor-friendly growth plan

Oct 29 2014

Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach

Jun 04 2019

'Beautiful baton pass' as Amgen picks up deCODE to validate drug targets

Dec 11 2012

Related Companies

Amgen, Inc.

Additional Topics

Clinical Trials Drug Approval Standards FDA Innovation Research & Development Regulation BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window